• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Isoxazoles

Professional Introduction to 2-(dimethyl-1,2-oxazol-4-yl)-2-methylpropanoic Acid (CAS No. 1512316-93-6)

2-(dimethyl-1,2-oxazol-4-yl)-2-methylpropanoic acid, identified by the CAS number 1512316-93-6, is a compound of significant interest in the field of pharmaceutical chemistry and bioorganic synthesis. This molecule, featuring a unique structural framework, has garnered attention due to its potential applications in drug development and as a key intermediate in synthetic pathways. The presence of a dimethyl-1,2-oxazol-4-yl moiety introduces a heterocyclic component that is known to enhance the pharmacological properties of various therapeutic agents.

The compound's structure consists of a β-keto acid derivative linked to an oxazole ring, which is a well-documented pharmacophore in medicinal chemistry. The oxazole ring itself is characterized by its ability to engage in hydrogen bonding and π-stacking interactions, making it a valuable component in designing molecules with improved binding affinity and selectivity. In recent years, there has been a growing interest in oxazole derivatives due to their demonstrated efficacy in treating a range of diseases, including infectious disorders and inflammatory conditions.

Recent studies have highlighted the role of 2-(dimethyl-1,2-oxazol-4-yl)-2-methylpropanoic acid as a versatile building block in the synthesis of novel bioactive molecules. Researchers have leveraged its structural features to develop inhibitors targeting specific enzymatic pathways involved in disease progression. For instance, derivatives of this compound have been explored as potential candidates for modulating kinases and other enzymes implicated in cancer metabolism. The ability of the oxazole ring to serve as a scaffold for drug design has been particularly noteworthy, with several preclinical studies demonstrating promising results.

The synthesis of 2-(dimethyl-1,2-oxazol-4-yl)-2-methylpropanoic acid involves multi-step organic transformations that require careful optimization to ensure high yield and purity. The introduction of the β-keto acid functionality allows for further derivatization, enabling the creation of diverse chemical libraries for high-throughput screening. Advances in synthetic methodologies have made it possible to produce this compound on a scalable basis, facilitating its use in both academic research and industrial applications.

In the realm of drug discovery, the pharmacokinetic properties of 2-(dimethyl-1,2-oxazol-4-yl)-2-methylpropanoic acid are under intense scrutiny. The compound's solubility, metabolic stability, and distribution profile are critical factors that determine its suitability for therapeutic use. Computational modeling has played a pivotal role in predicting these properties, allowing researchers to fine-tune the molecular structure for optimal pharmacokinetic performance. Such efforts are essential for translating laboratory findings into viable clinical candidates.

The oxazole moiety's electronic properties also contribute to the compound's reactivity and interaction with biological targets. This has led to investigations into its potential use as a chelating agent or as part of metal-based drug formulations. The ability to incorporate metal ions into therapeutic agents has opened up new avenues for treating metalloproteinase-mediated diseases and infections. Furthermore, the oxazole ring's stability under various conditions makes it an attractive choice for designing long-lasting pharmaceuticals.

Emerging research suggests that 2-(dimethyl-1,2-oxazol-4-yl)-2-methylpropanoic acid may have applications beyond traditional drug development. Its unique structural features make it suitable for use as an intermediate in materials science, particularly in the synthesis of advanced polymers and functional materials. The compound's ability to form stable complexes with other molecules also opens up possibilities for developing novel catalysts and chemical sensors.

The regulatory landscape surrounding this compound is another area of focus for researchers and industry professionals. Ensuring compliance with safety and environmental regulations is paramount as synthetic routes are refined and production scales up. Collaborative efforts between academia and regulatory bodies have been instrumental in establishing guidelines that promote responsible chemical management throughout the drug development lifecycle.

In conclusion, 2-(dimethyl-1,2-oxazol-4-yl)-2-methylpropanoic acid (CAS No. 1512316-93-6) represents a promising candidate for further exploration in pharmaceutical chemistry. Its unique structural attributes and potential applications across multiple disciplines underscore its importance as both a research tool and a commercial product. As synthetic methodologies continue to evolve and our understanding of biological systems deepens, this compound is poised to play an increasingly significant role in advancing therapeutic solutions.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)